Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro

Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy

(2013) P. M. Voorhees et al.   BLOOD

Recognition of the phenotype of thalidomide embryopathy in countries endemic for leprosy

(2013) Fernanda S.L. Vianna et al.   CLINICAL DYSMORPHOLOGY

Immunomodulatory drugs in multiple myeloma

(2013) Swati Andhavarapu et al.   Expert Review of Hematology

Isosteric analogs of lenalidomide and pomalidomide: Synthesis and biological activity

(2012) Alexander L. Ruchelman et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

(2012) P. G. Richardson et al.   BLOOD

Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

(2012) Matthew Hoffmann et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Antiangiogenic Therapeutic Approaches in Multiple Myeloma

(2012) Domenico Ribatti et al.   CURRENT CANCER DRUG TARGETS

Novel immunomodulatory compounds in multiple myeloma

(2012) Neeraj Saini et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

Identification of Thalidomide-Specific Transcriptomics and Proteomics Signatures during Differentiation of Human Embryonic Stem Cells

(2012) Kesavan Meganathan et al.   PLoS One

Nitric oxide rescues thalidomide mediated teratogenicity

(2012) Jamila H. Siamwala et al.   Scientific Reports

The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

(2011) Antonio Palumbo et al.   Expert Opinion On Drug Safety

Management of treatment-emergent peripheral neuropathy in multiple myeloma

(2011) P G Richardson et al.   LEUKEMIA

VEGF Signaling through Neuropilin 1 Guides Commissural Axon Crossing at the Optic Chiasm

(2011) Lynda Erskine et al.   NEURON

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

(2010) Michel Delforge et al.   LANCET ONCOLOGY

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Axon Guidance Molecules in Vascular Patterning

(2010) R. H. Adams et al.   Cold Spring Harbor Perspectives in Biology

Thalidomide-induced limb defects: resolving a 50-year-old puzzle

(2009) Neil Vargesson   BIOESSAYS

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

(2009) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation

(2009) C. Therapontos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide☆

(2009) Makoto Ema et al.   REPRODUCTIVE TOXICOLOGY

The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions

(2008) Ling Lu et al.   MICROVASCULAR RESEARCH